Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors
26.3.2021 09:00:00 EET | Business Wire | Press release
Regulatory News:
Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.
Åsa Riisberg, a Swedish citizen, was formerly Partner and member of the extended Executive Committee of the private equity firm EQT. She has served on various international boards with current board seats at Atlas Antibodies, Netcompany, F-Secure, Dagens Nyheter, Bonnier News and Bonnier Capital as well as at the Women in Finance Foundation. Åsa is also an Advisory Board Member at the Stockholm School of Economics and member of the Investment Committee at Cinder Invest. She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased that Åsa Riisberg will bring her expertise to the Board of Directors. Her broad knowledge and experience, particularly in the areas of investment management and operations are extremely valuable for Vifor Pharma. She will ideally complement the Board to assess the company’s business development and inorganic growth plans, aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005841/en/
Contact information
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 16:21:00 EEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
Meta Signs Agreement With AWS to Power Agentic AI on AWS Graviton Chips24.4.2026 15:10:00 EEST | Press release
Meta has signed an agreement to deploy AWS Graviton processors at scale. The deal marks a significant expansion of a long-standing partnership between the two companies as Meta builds its next generation of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424641117/en/ The deployment starts with tens of millions of Graviton cores, with the flexibility to expand as Meta's AI capabilities grow. The deal reflects a shift in how AI infrastructure gets built: while GPUs remain essential for training large models, the rise of agentic AI is creating massive demand for CPU-intensive workloads—real-time reasoning, code generation, search, and orchestrating multi-step tasks. Graviton5 is purpose-built for these workloads, giving Meta the processing power to run them efficiently at scale. The chips will power various workloads at Meta, including supporting the company’s AI efforts. That work requires infrastructure that can handle
Meta Signs Agreement With AWS to Power Agentic AI on AWS Graviton Chips24.4.2026 15:10:00 EEST | Press release
Meta has signed an agreement to deploy AWS Graviton processors at scale. The deal marks a significant expansion of a long-standing partnership between the two companies as Meta builds its next generation of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424641117/en/ The deployment starts with tens of millions of Graviton cores, with the flexibility to expand as Meta's AI capabilities grow. The deal reflects a shift in how AI infrastructure gets built: while GPUs remain essential for training large models, the rise of agentic AI is creating massive demand for CPU-intensive workloads—real-time reasoning, code generation, search, and orchestrating multi-step tasks. Graviton5 is purpose-built for these workloads, giving Meta the processing power to run them efficiently at scale. The chips will power various workloads at Meta, including supporting the company’s AI efforts. That work requires infrastructure that can handle
SLB Announces First-Quarter 2026 Results24.4.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422463846/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChange Mar. 31, 2026 Dec. 31, 2025 Mar. 31, 2025 Sequential Year-on-year Revenue $8,721 $9,745 $8,490 -11% 3% Income before taxes - GAAP basis $956 $943 $1,063 1% -10% Income before taxes margin - GAAP basis 11.0% 9.7% 12.5% 129 bps -156 bps Net income attributable to SLB - GAAP basis $752 $824 $797 -9% -6% Diluted EPS - GAAP basis $0.50 $0.55 $0.58 -9% -14% Adjusted EBITDA* $1,773 $2,331 $2,020 -24% -12% Adjusted EBITDA margin* 20.3% 23.9% 23.8% -358 bps -346 bps Pretax segment operating income* $1,321 $1,807 $1,556 -27% -15% Pretax segment operating margin* 15.2% 18.5% 18.3% -340 bps -318 bps Net income attributable to SLB, excluding charges & credits* $
SLB Announces First-Quarter 2026 Results24.4.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422463846/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChange Mar. 31, 2026 Dec. 31, 2025 Mar. 31, 2025 Sequential Year-on-year Revenue $8,721 $9,745 $8,490 -11% 3% Income before taxes - GAAP basis $956 $943 $1,063 1% -10% Income before taxes margin - GAAP basis 11.0% 9.7% 12.5% 129 bps -156 bps Net income attributable to SLB - GAAP basis $752 $824 $797 -9% -6% Diluted EPS - GAAP basis $0.50 $0.55 $0.58 -9% -14% Adjusted EBITDA* $1,773 $2,331 $2,020 -24% -12% Adjusted EBITDA margin* 20.3% 23.9% 23.8% -358 bps -346 bps Pretax segment operating income* $1,321 $1,807 $1,556 -27% -15% Pretax segment operating margin* 15.2% 18.5% 18.3% -340 bps -318 bps Net income attributable to SLB, excluding charges & credits* $
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom